Opiate abuse, innate immunity, and bacterial infectious diseases

被引:0
作者
Jinghua Wang
Roderick A. Barke
Jing Ma
Richard Charboneau
Sabita Roy
机构
[1] University of Minnesota,Division of Basic and Translational Research, Department of Surgery
[2] Veterans Affairs Medical Center,Department of Surgery
[3] Jilin University Norman Bethune Medical College,Department of Immunology
[4] University of Minnesota,Department of Pharmacology
来源
Archivum Immunologiae et Therapiae Experimentalis | 2008年 / 56卷
关键词
opiate; morphine; innate immunity; macrophages; neutrophils; dentritic cells; NK cells; γδ T lymphocytes; cytokines; bacterial infection;
D O I
暂无
中图分类号
学科分类号
摘要
The first line of defense against invading bacteria is provided by the innate immune system. Morphine and other opiates can immediately disrupt the body’s first line of defense against harmful external bacteria. Opiate, for example morphine, abuse degrades physical and physiologic barriers, and modulates phagocytic cells (macrophages, neutrophils) and, nonspecific cytotoxic T cells (γδ T), natural killer cells, and dendritic cells, that are functionally important for carrying out a rapid immune reaction to invading pathogens. In vitro studies with innate immune cells from experimental animals and humans and in vivo studies with animal models have shown that opiate abuse impairs innate immunity and is responsible for increased susceptibility to bacterial infection. However, to better understand the complex interactions between opiates, innate immunity, and bacterial infection and develop novel approaches to treat and even prevent bacterial infection in the opiate-abuse population, there is an urgent need to fill the numerous gaps in our understanding of the cellular and molecular mechanisms by which opiate abuse increases susceptibility to bacterial infection.
引用
收藏
页码:299 / 309
页数:10
相关论文
共 50 条
  • [41] The immunobiology of Campylobacter jejuni: Innate immunity and autoimmune diseases
    Phongsisay, Vongsavanh
    IMMUNOBIOLOGY, 2016, 221 (04) : 535 - 543
  • [42] Innate immunity in CKD-associated vascular diseases
    Zewinger, Stephen
    Schumann, Timo
    Fliser, Danilo
    Speer, Thimoteus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (11) : 1813 - 1821
  • [43] Involvement of innate immunity in the development of inflammatory and autoimmune diseases
    Tlaskalová-Hogenová, H
    Tucková, L
    Stepánková, R
    Hudcovic, T
    Palová-Jelínková, L
    Kozáková, H
    Rossmann, P
    Sanchez, D
    Cinová, J
    Hrncír, T
    Kverka, M
    Frolová, L
    Uhlig, H
    Powrie, F
    Bland, P
    AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 787 - 798
  • [44] Neural Regulation of Innate Immunity in Inflammatory Skin Diseases
    Huang, Xiaobao
    Li, Fengxian
    Wang, Fang
    PHARMACEUTICALS, 2023, 16 (02)
  • [45] The rat antigen-presenting lectin-like receptor complex influences innate immunity and development of infectious diseases
    J P Guo
    M Verdrengh
    A Tarkowski
    S Lange
    E Jennische
    J C Lorentzen
    R A Harris
    Genes & Immunity, 2009, 10 : 227 - 236
  • [46] Crosstalk Between Gut Microbiota and Innate Immunity and Its Implication in Autoimmune Diseases
    Jiao, Yuhao
    Wu, Li
    Huntington, Nicholas D.
    Zhang, Xuan
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [47] The rat antigen-presenting lectin-like receptor complex influences innate immunity and development of infectious diseases
    Guo, J. P.
    Verdrengh, M.
    Tarkowski, A.
    Lange, S.
    Jennische, E.
    Lorentzen, J. C.
    Harris, R. A.
    GENES AND IMMUNITY, 2009, 10 (03) : 227 - 236
  • [48] Imaging innate immunity*
    Gruneboom, Anika
    Aust, Oliver
    Cibir, Zuelal
    Weber, Flora
    Hermann, Dirk M.
    Gunzer, Matthias
    IMMUNOLOGICAL REVIEWS, 2022, 306 (01) : 293 - 303
  • [49] Innate Immunity and MASLD
    Meyer, Moritz
    Schwaerzler, Julian
    Jukic, Almina
    Tilg, Herbert
    BIOMOLECULES, 2024, 14 (04)
  • [50] Innate immunity and the heart
    Frantz, S
    Bauersachs, J
    Kelly, RA
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (10) : 1279 - 1290